TABLE 1.
ESBL genes detected, susceptibility (MIC in μg/ml), inhibitory Emax parameter estimates, and model fit for clinical isolates
| Bacterial species (isolate) | ESBL gene | MICa |
Model estimates and fit |
|||||
|---|---|---|---|---|---|---|---|---|
| CAZ | PIP-TAZ | log2 (MIC0) | Imax | IC50 | H | r2 | ||
| K. pneumoniae (Kp3) | CTX-M-15 | 64b | 32/4 | 9.32 | 6.52 | 2.60 | 1.57 | 0.94 |
| K. pneumoniae (KpK91) | CTX-M-15 | 64 | 32/4 | 9.03 | 4.75 | 1.36 | 4.00 | 0.97 |
| K. pneumoniae (Kp2301) | CTX-M-15 | >512 | >512/4 | 9.09 | 6.23 | 35.25 | 2.67 | 0.97 |
| E. coli (EcF65) | SHV-12 | >512 | 4/4 | 8.67 | 6.99 | 2.71 | 3.41 | 0.98 |
a
CAZ, ceftazidime; PIP-TAZ, piperacillin-tazobactam. TAZ MIC values for all isolates were >256 μg/ml.
b
Boldface denotes resistant phenotype according to CLSI breakpoints.